8 years ago

Proveca Secures £4 Million to Commercialize Children's Medicine

  • Proveca, a UK-based pharmaceutical company focused on developing medicines for children, has raised £4 million in funding

  • The round was led by Catapult Ventures, with growth debt financing provided by Kreos Capital

  • The company plans to use the funds for the commercial roll-out of Sialanar, a treatment for chronic pathological drooling in children.

      • ProblemHealthcare

      "Kids with medical conditions often experience chronic drooling. This can be embarrassing, lead to skin irritation, and impact their overall well-being. There haven’t been many good treatment options available for them."

      Solution

      "Proveca developed a drug called Sialanar that helps reduce drooling in children. This gives kids a chance to live more normal lives without the constant worry of drooling."

      Covered on